CN105431136B - 美他沙酮制剂 - Google Patents

美他沙酮制剂 Download PDF

Info

Publication number: CN105431136B
Authority: CN; China
Prior art keywords: metaxalone; dosage form; unit dosage; oral solid; particle size
Prior art date: 2013-07-22
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.): Expired - Fee Related

Application number

CN201480041432.5A

Other languages

English (en)

Chinese (zh)

Other versions

CN105431136A (zh

Inventor

H·W·伯士

Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)

Iceutica Inc

Original Assignee

Iceutica Inc

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2013-07-22

Filing date

2014-07-22

Publication date

2020-03-24

2014-07-22 Application filed by Iceutica Inc filed Critical Iceutica Inc

2016-03-23 Publication of CN105431136A publication Critical patent/CN105431136A/zh

2020-03-24 Application granted granted Critical

2020-03-24 Publication of CN105431136B publication Critical patent/CN105431136B/zh

Status Expired - Fee Related legal-status Critical Current

2034-07-22 Anticipated expiration legal-status Critical

Links

Images

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/42—Oxazoles
- A61K31/421—1,3-Oxazoles, e.g. pemoline, trimethadione
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
- A61K9/145—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic compounds
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D263/00—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
- C07D263/02—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings
- C07D263/08—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
- C07D263/16—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D263/18—Oxygen atoms
- C07D263/20—Oxygen atoms attached in position 2
- C07D263/24—Oxygen atoms attached in position 2 with hydrocarbon radicals, substituted by oxygen atoms, attached to other ring carbon atoms
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Medicinal Chemistry (AREA)
Pharmacology & Pharmacy (AREA)
Life Sciences & Earth Sciences (AREA)
Animal Behavior & Ethology (AREA)
General Health & Medical Sciences (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Epidemiology (AREA)
Bioinformatics & Cheminformatics (AREA)
Engineering & Computer Science (AREA)
Chemical Kinetics & Catalysis (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Chemical & Material Sciences (AREA)
Physical Education & Sports Medicine (AREA)
Orthopedic Medicine & Surgery (AREA)
Neurology (AREA)
Pain & Pain Management (AREA)
Rheumatology (AREA)
Medicinal Preparation (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)

CN201480041432.5A 2013-07-22 2014-07-22 美他沙酮制剂 Expired - Fee Related CN105431136B (zh)

Applications Claiming Priority (3)

Application Number	Priority Date	Filing Date	Title
US201361857199P	2013-07-22	2013-07-22
US61/857,199		2013-07-22
PCT/US2014/047701 WO2015013336A1 (en)	2013-07-22	2014-07-22	Formulation of metaxalone

Publications (2)

Publication Number	Publication Date
CN105431136A CN105431136A (zh)	2016-03-23
CN105431136B true CN105431136B (zh)	2020-03-24

Family

ID=52393794

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
CN201480041432.5A Expired - Fee Related CN105431136B (zh)	2013-07-22	2014-07-22	美他沙酮制剂

Country Status (17)

Country	Link
US (7)	US20160159756A1 (2)
EP (1)	EP3024440B1 (2)
JP (1)	JP6453876B2 (2)
KR (1)	KR20160039608A (2)
CN (1)	CN105431136B (2)
AU (1)	AU2014293193A1 (2)
BR (1)	BR112016001395A8 (2)
CA (1)	CA2918908A1 (2)
CL (1)	CL2016000171A1 (2)
DK (1)	DK3024440T3 (2)
IL (1)	IL243447A0 (2)
MX (1)	MX365591B (2)
MY (1)	MY181226A (2)
RU (1)	RU2684914C2 (2)
SG (2)	SG10201800491RA (2)
WO (1)	WO2015013336A1 (2)
ZA (1)	ZA201600408B (2)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US9526734B2 (en)	2014-06-09	2016-12-27	Iceutica Pty Ltd.	Formulation of meloxicam
US20200405693A1 (en)	2019-06-25	2020-12-31	Primus Pharmaceuticals, Inc.	Reduced dose metaxalone formulations

Citations (2)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US7714006B1 (en) *	2001-12-03	2010-05-11	King Pharmaceuticals Research & Development, Inc.	Methods of modifying the bioavailability of metaxalone
CN102438621A (zh) *	2009-04-24	2012-05-02	伊休蒂卡有限公司	美他沙酮的新剂型

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US5500331A (en)	1994-05-25	1996-03-19	Eastman Kodak Company	Comminution with small particle milling media
US5478705A (en)	1994-05-25	1995-12-26	Eastman Kodak Company	Milling a compound useful in imaging elements using polymeric milling media
US6407128B1 (en) *	2001-12-03	2002-06-18	Elan Pharmaceuticals, Inc.	Method for increasing the bioavailability of metaxalone
AU2003276688A1 (en) *	2002-09-02	2004-03-19	Sun Pharmaceutical Industries Limited	Pharmaceutical composition of metaxalone with enhanced oral bioavailability
ATE415946T1 (de) *	2003-08-08	2008-12-15	Elan Pharma Int Ltd	Neue metaxalon-zusammensetzungen
US20050276844A1 (en) *	2004-03-08	2005-12-15	Spiridon Spireas	Bioavailable compositions of metaxalone and processes for producing the same
US20120093928A1 (en) *	2007-08-09	2012-04-19	Ranbaxy Laboratories Limited	Oral metaxalone compositions
AP3138A (en) *	2009-04-24	2015-02-28	Iceutica Pty Ltd	Production of encapsulated nanoparticles at high volume fractions
RU2499595C1 (ru) *	2012-07-03	2013-11-27	Государственное бюджетное образовательное учреждение высшего профессионального образования "Воронежская государственная медицинская академия им. Н.Н. Бурденко" Министерства здравоохранения и социального развития Российской Федерации	Способ повышения качества жизни и улучшения способностей к выполнению профессиональной деятельности у пациентов с остеоартрозом, выполняющих водительские и диспетчерско-операторские функции

2014
- 2014-07-22 SG SG10201800491RA patent/SG10201800491RA/en unknown
- 2014-07-22 JP JP2016529842A patent/JP6453876B2/ja not_active Expired - Fee Related
- 2014-07-22 CA CA2918908A patent/CA2918908A1/en not_active Abandoned
- 2014-07-22 MX MX2016001019A patent/MX365591B/es active IP Right Grant
- 2014-07-22 EP EP14830224.3A patent/EP3024440B1/en not_active Not-in-force
- 2014-07-22 CN CN201480041432.5A patent/CN105431136B/zh not_active Expired - Fee Related
- 2014-07-22 MY MYPI2016700223A patent/MY181226A/en unknown
- 2014-07-22 AU AU2014293193A patent/AU2014293193A1/en not_active Abandoned
- 2014-07-22 BR BR112016001395A patent/BR112016001395A8/pt not_active IP Right Cessation
- 2014-07-22 US US14/906,703 patent/US20160159756A1/en not_active Abandoned
- 2014-07-22 RU RU2016105763A patent/RU2684914C2/ru active
- 2014-07-22 WO PCT/US2014/047701 patent/WO2015013336A1/en not_active Ceased
- 2014-07-22 KR KR1020167001873A patent/KR20160039608A/ko not_active Ceased
- 2014-07-22 SG SG11201600264TA patent/SG11201600264TA/en unknown
- 2014-07-22 DK DK14830224.3T patent/DK3024440T3/en active
2016
- 2016-01-03 IL IL243447A patent/IL243447A0/en unknown
- 2016-01-19 ZA ZA2016/00408A patent/ZA201600408B/en unknown
- 2016-01-22 CL CL2016000171A patent/CL2016000171A1/es unknown
2017
- 2017-09-05 US US15/696,125 patent/US20180148422A1/en not_active Abandoned
2018
- 2018-11-13 US US16/190,104 patent/US20190152930A1/en not_active Abandoned
2020
- 2020-05-15 US US16/875,931 patent/US20210101873A1/en not_active Abandoned
2022
- 2022-02-07 US US17/666,465 patent/US20220235017A1/en not_active Abandoned
2023
- 2023-07-12 US US18/221,353 patent/US20240150304A1/en not_active Abandoned
2024
- 2024-11-21 US US18/955,748 patent/US20250084043A1/en not_active Abandoned

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US7714006B1 (en) *	2001-12-03	2010-05-11	King Pharmaceuticals Research & Development, Inc.	Methods of modifying the bioavailability of metaxalone
CN102438621A (zh) *	2009-04-24	2012-05-02	伊休蒂卡有限公司	美他沙酮的新剂型

Also Published As

Publication number	Publication date
US20180148422A1 (en)	2018-05-31
US20190152930A1 (en)	2019-05-23
ZA201600408B (en)	2017-04-26
IL243447A0 (en)	2016-02-29
AU2014293193A1 (en)	2016-01-28
CA2918908A1 (en)	2015-01-29
US20220235017A1 (en)	2022-07-28
SG11201600264TA (en)	2016-02-26
MX365591B (es)	2019-06-07
WO2015013336A1 (en)	2015-01-29
MX2016001019A (es)	2016-07-19
SG10201800491RA (en)	2018-03-28
EP3024440A4 (en)	2017-01-25
HK1225301A1 (en)	2017-09-08
US20250084043A1 (en)	2025-03-13
BR112016001395A8 (pt)	2020-01-14
RU2016105763A (ru)	2017-08-29
CN105431136A (zh)	2016-03-23
RU2016105763A3 (2)	2018-06-13
JP6453876B2 (ja)	2019-01-16
JP2016527251A (ja)	2016-09-08
HK1222570A1 (zh)	2017-07-07
MY181226A (en)	2020-12-21
KR20160039608A (ko)	2016-04-11
CL2016000171A1 (es)	2016-07-01
RU2684914C2 (ru)	2019-04-16
BR112016001395A2 (pt)	2017-07-25
US20210101873A1 (en)	2021-04-08
US20160159756A1 (en)	2016-06-09
EP3024440B1 (en)	2018-11-28
EP3024440A1 (en)	2016-06-01
DK3024440T3 (en)	2019-03-11
US20240150304A1 (en)	2024-05-09

Legal Events

Date	Code	Title	Description
2016-03-23	C06	Publication
2016-03-23	PB01	Publication
2016-04-20	C10	Entry into substantive examination
2016-04-20	SE01	Entry into force of request for substantive examination
2017-07-07	REG	Reference to a national code	Ref country code: HK Ref legal event code: DE Ref document number: 1222570 Country of ref document: HK
2020-03-24	GR01	Patent grant
2020-03-24	GR01	Patent grant
2022-07-08	CF01	Termination of patent right due to non-payment of annual fee	Granted publication date: 20200324 Termination date: 20210722
2022-07-08	CF01	Termination of patent right due to non-payment of annual fee

Publication	Publication Date	Title
JP6239709B2 (ja)	2017-11-29	インドメタシンの新規製剤
CA2907415C (en)	2022-04-05	Abiraterone acetate formulation
HK1231383A1 (zh)	2017-12-22	双氯芬酸的新剂型
US9808468B2 (en)	2017-11-07	Formulation of meloxicam
US20250084043A1 (en)	2025-03-13	Formulation of metaxalone
HK1222570B (zh)	2021-03-12	美他沙酮製劑
HK1225301B (en)	2020-01-10	Formulation of metaxalone
HK1233538A1 (zh)	2018-02-02	双氯芬酸的新剂型
HK1242624A1 (en)	2018-06-29	A novel formulation of meloxicam
HK1232808A1 (en)	2018-01-19	A novel formulation of diclofenac